8-K: Oragenics Submits Investigators Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury

Oragenics, Inc. has submitted its Investigators Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia, marking a significant step in developing a treatment for mild traumatic brain injury (mTBI).

Summary

• Oragenics, Inc. has announced the submission of its Investigators Brochure (IB) application for a Phase II clinical trial of ONP-002 in Australia.
• ONP-002 is a novel intranasal neurosteroid being developed as a potential treatment for mild traumatic brain injury (mTBI), also known as concussion.
• Preclinical results have shown ONP-002's potential to reduce inflammation, oxidative stress, and brain swelling.
• A prior Phase I study in healthy adults confirmed the drug's safety and tolerability at multiple intranasal doses.
• The Phase II study aims to establish the feasibility of acute intranasal administration in mTBI patients and generate initial proof-of-concept data.
• The study will involve cognitive testing, visual motor testing, and biomarker analysis.
• The IB provides investigators with comprehensive data on ONP-002, including its safety, pharmacokinetics, and pharmacodynamics.
• The Phase II trial is a randomized, double-blind, placebo-controlled study designed to assess the feasibility, safety, tolerability, blood biomarker response, and pharmacokinetics/pharmacodynamics of ONP-002 in adults with mTBI.
• The study is designed to enroll up to 40 participants, with 20 receiving ONP-002 and 20 receiving a placebo.
• Participants will receive a total of nine doses over five days, with the first dose administered within 12 hours of injury.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the progress of ONP-002, highlighting the submission of the Investigators Brochure and the anticipation of initiating the Phase II clinical trial. However, it also acknowledges the risks and uncertainties associated with forward-looking statements.

Positives

• The submission of the Investigators Brochure is a critical step forward in advancing the clinical program for ONP-002.
• ONP-002 has shown promising preclinical results.
• The Phase I study confirmed the drug's safety and tolerability.
• The Phase II trial is well-designed to assess the feasibility, safety, and efficacy of ONP-002.
• There is a significant unmet medical need for FDA-approved drug therapies for concussions.

Risks

• The success of the Phase II trial is not guaranteed.
• Regulatory approvals are required to initiate the clinical trial.
• The trial may not enroll the target number of participants.
• The results of the trial may not be positive.
• The company's forward-looking statements are subject to risks and uncertainties.

Future Outlook

The company anticipates receiving final regulatory approvals that should allow them to initiate the clinical trial in the coming weeks and are focused on ensuring a smooth trial launch and look forward to sharing updates as they progress.

Management Comments

• Janet Huffman, Interim CEO of Oragenics, stated that the submission of the Investigators Brochure application marks a critical step forward in advancing their clinical program for ONP-002.
• She also mentioned that the submission brings them closer to initiating their clinical trial and that they remain committed to delivering a much-needed therapeutic option for patients suffering from mTBI.

Industry Context

The announcement is relevant in the context of the unmet medical need for FDA-approved drug therapies for concussions, as there are currently no such treatments available.

Comparison to Industry Standards

• Several companies are developing treatments for traumatic brain injury, including but not limited to BioBlast Pharma and BrainStorm Cell Therapeutics.
• Oragenics' approach with an intranasal neurosteroid is unique, as many other companies are focusing on different mechanisms of action, such as cell therapies or other small molecules.
• The Phase II trial design appears to be consistent with industry standards for early-stage clinical trials in this indication.

Stakeholder Impact

• Positive impact on shareholders due to the advancement of the clinical program.
• Potential positive impact on patients suffering from mTBI if the trial is successful.
• Potential positive impact on investigators involved in the clinical trial.

Next Steps

• Receiving final regulatory approvals to initiate the Phase II clinical trial.
• Initiating the Phase II clinical trial in Australia.
• Sharing updates on the progress of the clinical trial.

Key Dates